Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, Coward J, Fourie S, Kurochkin A, Malan DR, Mant A, Sharma V, Shue H, Tazbirkova A, Berciano-Guerrero MA, Charoentum C, Dalle S, Dechaphunkul A, Dudnichenko O, Koralewski P, Lugowska I, Montaudié H, Muñoz-Couselo E, Sriuranpong V, Oliviero J, Desai J. Clingan P, et al. Among authors: dalle s. J Immunother Cancer. 2023 Oct;11(10):e007637. doi: 10.1136/jitc-2023-007637. J Immunother Cancer. 2023. PMID: 37848259 Free PMC article.
Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A, Beylot-Barry M, Ram-Wolff C, Mear JB, Dalle S, d'Incan M, Ingen-Housz-Oro S, Orvain C, Abraham J, Dereure O, Charbonnier A, Cornillon J, Longvert C, Barete S, Boulinguez S, Wierzbicka-Hainaut E, Aubin F, Rubio MT, Bernard M, Schmidt-Tanguy A, Houot R, Pham-Ledard A, Michonneau D, Brice P, Labussière-Wallet H, Bouaziz JD, Grange F, Moins-Teisserenc H, Jondeau K, Michel L, Mourah S, Battistella M, Daguindau E, Loschi M, Picard A, Franck N, Maillard N, Huynh A, Nguyen S, Marçais A, Chaby G, Ceballos P, Le Corre Y, Maury S, Bay JO, Adamski H, Bachy E, Forcade E, Socié G, Bagot M, Chevret S, Peffault de Latour R; CUTALLO Investigators; Groupe Français d'Etude des Lymphomes Cutanés; Société Française de Greffe de Moëlle et Thérapie Cellulaire. de Masson A, et al. Among authors: dalle s. Lancet. 2023 Jun 10;401(10392):1941-1950. doi: 10.1016/S0140-6736(23)00329-X. Epub 2023 Apr 24. Lancet. 2023. PMID: 37105210
Evolving Practices in Immune-Related Adverse Event Management: Insights From the IMMUCARE Multidisciplinary Board.
Varnier R, Fontaine-Delaruelle C, Freymond N, Essongue A, Bouali A, Boschetti G, Lebosse F, Tartas S, Milley S, Cugnet-Anceau C, Novel-Catin E, Joubert B, Massy E, Dalle S, Maillet D. Varnier R, et al. Among authors: dalle s. JCO Oncol Pract. 2024 Jul 22:OP2400042. doi: 10.1200/OP.24.00042. Online ahead of print. JCO Oncol Pract. 2024. PMID: 39038252
Erratum: Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational cohort study.
Bozonnat A, Beylot-Barry M, Dereure O, D'Incan M, Quereux G, Guenova E, Perier-Muzet M, Dalle S, Grange F, Viguier MA, Ram-Wolff C, Feldmeyer L, Beltraminelli H, Bonnet N, Amatore F, Maubec E, Franck N, Machet L, Chasset F, Brunet-Possenti F, Bouaziz JD, Battistella M, Donzel M, Pham-Ledard A, Bejar C, Moins-Teisserenc H, Mourah S, Saiag P, Hainaut E, Michel C, Bens G, Adamski H, Aubin F, Boulinguez S, Joly P, Tedbirt B, Templier I, Troin L, Montaudié H, Ingen-Housz-Oro S, Faiz S, Mortier L, Dobos G, Bagot M, Resche-Rigon M, Montlahuc C, Serret-Larmande A, de Masson A; Cutaneous Lymphomas French Study Group. Bozonnat A, et al. Among authors: dalle s. EClinicalMedicine. 2024 Dec 6;79:102979. doi: 10.1016/j.eclinm.2024.102979. eCollection 2025 Jan. EClinicalMedicine. 2024. PMID: 39720605 Free PMC article.
When to stop immunotherapy for advanced melanoma: the emulated target trials.
Amiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, Leccia MT, Maubec E, Arnault JP, Brunet-Possenti F, De Quatrebarbes J, Granel-Brocard F, Gaudy-Marqueste C, Pages C, Stoebner PE, Saiag P, Lesimple T, Dupuy A, Legoupil D, Montaudié H, Oriano B, Lebbe C, Porcher R. Amiot M, et al. Among authors: dalle s. EClinicalMedicine. 2024 Dec 4;78:102960. doi: 10.1016/j.eclinm.2024.102960. eCollection 2024 Dec. EClinicalMedicine. 2024. PMID: 39717261 Free PMC article.
Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
Tawbi HA, Hodi FS, Lipson EJ, Schadendorf D, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas H, Lao CD, Janoski De Menezes J, Dalle S, Arance AM, Grob JJ, Ratto B, Rodriguez S, Mazzei A, Dolfi S, Long GV. Tawbi HA, et al. Among authors: dalle s. J Clin Oncol. 2024 Dec 13:JCO2401124. doi: 10.1200/JCO.24.01124. Online ahead of print. J Clin Oncol. 2024. PMID: 39671533
Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.
Le Brun IC, Dalle S, Mortier L, Dereure O, Rat SD, Dutriaux C, Leccia MT, Legoupil D, Montaudié H, De Quatrebarbes J, Gaudy-Marqueste C, Maubec E, Saiag P, Pagès C, Possenti FB, Granel-Brocard F, Porcher R, Lefevre W, Lebbé C, Kempf E. Le Brun IC, et al. Among authors: dalle s. Cancer. 2025 Jan 1;131(1):e35679. doi: 10.1002/cncr.35679. Epub 2024 Dec 8. Cancer. 2025. PMID: 39645590 Free PMC article.
500 results